Recent studies have identified that NG2 functions in various cell types and NG2 levels are increased in many aggressive cancers, including melanomas [16], gliomas [17], mesotheliomas [18], sarcomas [19], anaplastic thyroid cancer [20], triple-negative breast cancers [21] and hepatocellular carcinoma [22]. This evidence concerns the gene CSPG4 and triple-negative breast carcinoma.